Meeting
2019 ASCO Annual Meeting
A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
Authors
Drew W. Rasco
South Texas Accelerated Research Therapeutics (START), San Antonio, TX
Drew W. Rasco , Nehal J. Lakhani , Yufeng Li , Lichuang Men , Hengbang Wang , Jiao Ji , Yuefen Tang , ZHIYAN LIANG , Alex Amaya , Kathy Estkowski , Joan Sun , Yingjie Huang , Dajun Yang , Yifan Zhai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02935907
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3126)
DOI
10.1200/JCO.2019.37.15_suppl.3126
Abstract #
3126
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors.
First Author: Anthony W. Tolcher
Poster
2020 ASCO Virtual Scientific Program
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
First Author: Xing Zhang
Poster
2022 ASCO Annual Meeting
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
First Author: Meredith McKean
Poster
2019 ASCO Annual Meeting
A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.
First Author: Xing Zhang